TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26820220

Group type: EXPERIMENTAL
Intervention: Sustained lung inflation (SLI) at birth (25 cmH2O for 15 seconds)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (CPAP or assistance as per AAP recommendations)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Sustained lung inflation (SLI) at birth
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 185
Study: 24990426

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) intervention
Number of subjects: 7187

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 7187

Group type: EXPERIMENTAL
Intervention: Baseline triglycerides
Number of subjects: 7187
Study: 22843897

Group type: EXPERIMENTAL
Intervention: Gentle strength training (lifting standardized weights weekly at 50% of h1RM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional gymnastic exercises
Number of subjects: 0
Study: 21092037

Group type: EXPERIMENTAL
Intervention: Transfusion therapy after cardiopulmonary bypass with fibrinogen administration combined with traditional transfusion, guided by TEG (Group F)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Traditional transfusion guided by clinical experiences only (Group C)
Number of subjects: 31
Study: 18510730

Group type: EXPERIMENTAL
Intervention: Case management by advanced practice nurses
Number of subjects: 35
Study: 15677796

Group type: EXPERIMENTAL
Intervention: Endothelial biopsy and RT-PCR analysis of RAGE and MCP-1 transcripts
Number of subjects: 12
Study: 12750062

Group type: EXPERIMENTAL
Intervention: NG‐monomethyl‐L‐arginine (L‐NMMA; 3 mg/kg over 5 min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NG‐monomethyl‐L‐arginine (L‐NMMA; 6 mg/kg over 5 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NG‐monomethyl‐L‐arginine (L‐NMMA; 3 mg/kg and 6 mg/kg)
Number of subjects: 12
Study: 10371111

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg daily for 4 weeks)
Number of subjects: 77

Group type: COMPARATOR
Intervention: CABG without preoperative lipid control
Number of subjects: 77
Study: 9009787

Group type: EXPERIMENTAL
Intervention: Awareness of mortality
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symbolic immortality (two forms)
Number of subjects: 0
Study: 1642662

Group type: EXPERIMENTAL
Intervention: 100 mg oral tiludronate
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 200 mg oral tiludronate
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 400 mg oral tiludronate
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 800 mg oral tiludronate
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 6881451

Group type: EXPERIMENTAL
Intervention: Primary common bile duct closure
Number of subjects: 117

Group type: COMPARATOR
Intervention: T‐tube drainage
Number of subjects: 117
Study: 31403974

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (low infusion rate: 0.5 μg · kg · h; moderate infusion rate: 1.5 μg · kg · h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propofol (low infusion rate: 42 μg · kg · min; moderate infusion rate: 83 μg · kg · min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (low infusion rate)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propofol (low infusion rate)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (moderate infusion rate)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propofol (moderate infusion rate)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Propofol (both infusion rates)
Number of subjects: 12
Study: 28771064

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU of cholecalciferol every two weeks for 11-12 weeks)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 57
Study: 26088568

Group type: EXPERIMENTAL
Intervention: Practice nurse‐mediated intervention
Number of subjects: 1492

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 1492

Group type: COMPARATOR
Intervention: Practice nurse‐mediated usual care
Number of subjects: 1492

Group type: COMPARATOR
Intervention: Standard usual care
Number of subjects: 1492
Study: 24738117

Group type: EXPERIMENTAL
Intervention: Suture closure of the subcutaneous tissue
Number of subjects: 361

Group type: COMPARATOR
Intervention: Non-closure of the subcutaneous tissue
Number of subjects: 361
Study: 21236699

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 3069

Group type: EXPERIMENTAL
Intervention: Lipophilic statins
Number of subjects: 3069

Group type: COMPARATOR
Intervention: Lipid-lowering medications (LLMs) including statins
Number of subjects: 3069
Study: 19216654

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) combined with ginsenosides (GS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dexamethasone (Dex)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ginsenosides (GS)
Number of subjects: 120
Study: 18070466

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 150

Group type: COMPARATOR
Intervention: No statin
Number of subjects: 150
Study: 15142010

Group type: EXPERIMENTAL
Intervention: High Carbohydrate (HC) meal (79% carbohydrate, 20% protein, 1% fat)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High Fat (HF) meal (37% carbohydrate, 18% protein, 45% fat)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water (CON)
Number of subjects: 9
Study: 11520776

Group type: EXPERIMENTAL
Intervention: Favorable risk group (t(15;17), t(8;21), or inv(16))
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Normal karyotype
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Other noncomplex abnormalities
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Complex karyotype
Number of subjects: 1065
Study: 16296679

Group type: EXPERIMENTAL
Intervention: Hip protectors (Sahvatex, Denmark) fitted into specially designed undergarments, used over a 3-month period.
Number of subjects: 101
Study: 7945126

Group type: EXPERIMENTAL
Intervention: cinnarizine 50 mg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: cinnarizine 25 mg
Number of subjects: 95

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 95
Study: 2855116

Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alcohol (1.2 g/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Marijuana (1.3% delta 9‐THC)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Marijuana (2.7% delta 9‐THC)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Alcohol (0 g/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Marijuana (0% delta 9‐THC)
Number of subjects: 6
Study: 31788849

Group type: EXPERIMENTAL
Intervention: 50 mg rectal diclofenac administered 30 minutes before ERCP
Number of subjects: 297

Group type: COMPARATOR
Intervention: Control group (no diclofenac)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Both groups (diclofenac and control)
Number of subjects: 297
Study: 29698251

Group type: EXPERIMENTAL
Intervention: Tailored Activity Program‐Brazilian version (TAP‐BR) over 4 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (wait-list control group)
Number of subjects: 30
Study: 25953193

Group type: EXPERIMENTAL
Intervention: Probiotic supplements (Lactobacillus reuteri)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (topical oil application and lozenges)
Number of subjects: 49
Study: 24756186

Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg oral)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 23086785

Group type: EXPERIMENTAL
Intervention: Transapical (TA) procedure
Number of subjects: 105

Group type: COMPARATOR
Intervention: Transfemoral (TF) procedure
Number of subjects: 105
Study: 20420674

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cortisone
Number of subjects: 60
Study: 18231834

Group type: EXPERIMENTAL
Intervention: Ligasure hemorrhoidectomy
Number of subjects: 273

Group type: COMPARATOR
Intervention: Conventional diathermy hemorrhoidectomy
Number of subjects: 273
Study: 15746470

Group type: EXPERIMENTAL
Intervention: Sun-protective clothing (investigator-provided garments made from fabrics with ultraviolet protection factors rated very good to excellent)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 652
Study: 12504938

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate 20 mg
Number of subjects: 0
Study: 10634836

Group type: EXPERIMENTAL
Intervention: Early sodium supplementation (4 mmol/kg/day starting on the second day after birth)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Delayed sodium supplementation (4 mmol/kg/day starting when weight loss of 6% of birthweight was achieved)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Delayed sodium supplementation
Number of subjects: 46
Study: 8859725

Group type: EXPERIMENTAL
Intervention: THERATOPE STn‐KLH cancer vaccine emulsified in DETOX adjuvant
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Low‐dose intravenous cyclophosphamide before ASI
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Postimmunization increase in anti‐OSM IgM titer
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Increased anti‐OSM IgG titers
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Increased pre‐ASI CA‐125 serum levels
Number of subjects: 85

Group type: COMPARATOR
Intervention: Anti‐KLH antibody titers
Number of subjects: 85
Study: 1516489

Group type: EXPERIMENTAL
Intervention: Intermittent glyburide therapy (2 weeks on, 2 weeks off)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Continuous glyburide therapy
Number of subjects: 28
Study: 6509985

Group type: EXPERIMENTAL
Intervention: Digital insertion of IUD
Number of subjects: 114

Group type: COMPARATOR
Intervention: Surgical forceps insertion of IUD
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Inexperienced inserters
Number of subjects: 114
Study: 30789347

Group type: EXPERIMENTAL
Intervention: Education Against Tobacco (EAT) intervention (90 minutes of mentoring in a classroom setting)
Number of subjects: 2348

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2348

Group type: EXPERIMENTAL
Intervention: Education Against Tobacco (EAT) intervention
Number of subjects: 2348
Study: 29253154

Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 788

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 788
Study: 26540163

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention combining telemonitoring, medication management, self-management support, and depression management.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 24910934

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA; onabotulinumtoxinA) injections; Female participants received 29 units; Male participants received 39 units
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA; onabotulinumtoxinA) injections
Number of subjects: 30
Study: 21702046

Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT) screening
Number of subjects: 4407

Group type: EXPERIMENTAL
Intervention: Two-stage recruitment for FS and FIT screening
Number of subjects: 4407

Group type: EXPERIMENTAL
Intervention: FIT screening
Number of subjects: 4407

Group type: EXPERIMENTAL
Intervention: Two-stage recruitment
Number of subjects: 4407
Study: 20368402

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ) and Artesunate (AS) combination therapy
Number of subjects: 54
Study: 18071282

Group type: EXPERIMENTAL
Intervention: 95% ethanol
Number of subjects: 74

Group type: COMPARATOR
Intervention: 20% hypertonic saline (HS)
Number of subjects: 74
Study: 15996811

Group type: EXPERIMENTAL
Intervention: Doxazosin gastrointestinal therapeutic system (DOX GITS) 4 mg/d
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 14507273

Group type: EXPERIMENTAL
Intervention: Oral calcium (Ca) 1 g
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral calcium (Ca) 2 g
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral calcium (Ca) 4 g
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral calcium (Ca)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Plateletpheresis
Number of subjects: 23
Study: 10768522

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 3 mg granisetron
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 5 mg tropisetron
Number of subjects: 106
Study: 8644427

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy including 5-fluorouracil and leucovorin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluorouracil in combination with levamisole or leucovorin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study: 1998792

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Stopping the combined oral contraceptive pill
Number of subjects: 24
Study: 6147193

Group type: EXPERIMENTAL
Intervention: SCH 399 syrup (combination of azatadine maleate, pseudoephedrine sulfate, and dextromethorphan hydrobromide)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Expectorant containing diphenhydramine hydrochloride
Number of subjects: 60
Study: 28392194

Group type: EXPERIMENTAL
Intervention: EB-NLFC hearing aids
Number of subjects: 14

Group type: COMPARATOR
Intervention: NLFC hearing aids
Number of subjects: 14
Study: 28271540

Group type: EXPERIMENTAL
Intervention: V0034CR emollient
Number of subjects: 335

Group type: COMPARATOR
Intervention: No emollient
Number of subjects: 335
Study: 26317458

Group type: EXPERIMENTAL
Intervention: Blended learning (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video assignments (specifics not provided)
Number of subjects: 0
Study: 24169289

Group type: EXPERIMENTAL
Intervention: Anti-adhesion modified chitosan (Baifeimi) applied during surgery
Number of subjects: 42

Group type: COMPARATOR
Intervention: Routine chest closing without application of Baifeimi (Control)
Number of subjects: 42
Study: 21415838

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study: 18222194

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 410

Group type: COMPARATOR
Intervention: Overall
Number of subjects: 410

Group type: COMPARATOR
Intervention: Latanoprost vs Travoprost
Number of subjects: 410
Study: 16779849

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 19

Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 19
Study: 14579028

Group type: EXPERIMENTAL
Intervention: Nonoperative therapy, including modification of sports and recreational activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Operative options such as resecting arthroscopic procedures, repair of damaged articular cartilage, osteotomy, and unicompartmental knee arthroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study: 10862585

Group type: EXPERIMENTAL
Intervention: Intravenous flecainide (n = 39)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Oral flecainide (n = 40)
Number of subjects: 79
Study: 8936895

Group type: COMPARATOR
Intervention: LAX
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ETT
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: BF
Number of subjects: 44
Study: 1420057

Group type: EXPERIMENTAL
Intervention: 500 mg of Diamox Sustets (acetazolamide) 1 hour preoperatively
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Peroperative intracameral Miochol (acetylcholine)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined treatment of acetazolamide and acetylcholine
Number of subjects: 36
Study: 6536517

Group type: EXPERIMENTAL
Intervention: Gases humidified and heated to 37 degrees C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gases humidified and heated to 40 degrees C
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group with anaesthetic gases humidified by a sponge heat and moisture exchanger
Number of subjects: 30
Study: 31063198

Group type: EXPERIMENTAL
Intervention: Milk microbiome
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Infant oral microbiome
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Maternal and infant fecal microbiomes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Microbial community structures
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Complex microbial interactions
Number of subjects: 21
Study: 30092157

Group type: EXPERIMENTAL
Intervention: 1000 IU/day vitamin D (cholecalciferol, Calcirol® sachet) administered as a stat dose of 90,000 IU every three months.
Number of subjects: 60

Group type: COMPARATOR
Intervention: 400 IU/day vitamin D (cholecalciferol) administered as a stat dose of 36,000 IU every three months.
Number of subjects: 60
Study: 27485377

Group type: EXPERIMENTAL
Intervention: Bayesian adaptive patient enrollment restriction (BAPER) approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Four-parameter change-point model
Number of subjects: 0
Study: 24770498

Group type: EXPERIMENTAL
Intervention: Topical potassium hydroxide therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 48
Study: 21458108

Group type: EXPERIMENTAL
Intervention: Circumferential subannular grafting (group A)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional underlay tympanoplasty (group B)
Number of subjects: 63
Study: 20458465

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical tibial nerve stimulation (TTNS) in addition to standard therapy (bladder retraining and pelvic floor muscle exercises)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard therapy (bladder retraining and pelvic floor muscle exercises)
Number of subjects: 51
Study: 17188941

Group type: EXPERIMENTAL
Intervention: Sample size calculation considering center effect
Number of subjects: 0
Study: 16390031

Group type: EXPERIMENTAL
Intervention: Tauc‐FP
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MUGA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MIBI‐FP
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MIBI‐gFP
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GSPECT
Number of subjects: 40
Study: 12483094

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Isopropyl unoprostone 0.12% twice daily for 8 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 48

Group type: COMPARATOR
Intervention: Isopropyl unoprostone
Number of subjects: 48
Study: 10682558

Group type: EXPERIMENTAL
Intervention: Epimedium compound granules
Number of subjects: 120

Group type: COMPARATOR
Intervention: Su‐Guan‐Bian (Control)
Number of subjects: 120
Study: 7781793

Group type: EXPERIMENTAL
Intervention: HemeSelect at 1:8 dilution
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: HemeSelect at 1:16 dilution
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: HemeSelect at 1:32 dilution
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: HemeSelect at 1:64 dilution
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: HemeSelect at 1:128 dilution
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Haemoccult
Number of subjects: 1489
Study: 2650730

Group type: EXPERIMENTAL
Intervention: Alfuzosin 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 589554

Group type: EXPERIMENTAL
Intervention: Combination therapy including vincristine at 3-week intervals
Number of subjects: 462

Group type: COMPARATOR
Intervention: Azathioprine-prednisone
Number of subjects: 462

Group type: COMPARATOR
Intervention: Melphalan-cyclophosphamide-BCNU-prednisone
Number of subjects: 462

Group type: COMPARATOR
Intervention: Other therapies or no therapy
Number of subjects: 462
Study: 31882232

Group type: EXPERIMENTAL
Intervention: Individualised nutritional support intervention
Number of subjects: 2028

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 2028

Group type: EXPERIMENTAL
Intervention: NRS score increase
Number of subjects: 2028
Study: 31576450

Group type: EXPERIMENTAL
Intervention: PFMT + WL
Number of subjects: 22
Study: 27632835

Group type: EXPERIMENTAL
Intervention: Sustained traction (ST)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oscillatory traction (OT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 20
Study: 26179284

Group type: EXPERIMENTAL
Intervention: Probiotics (a widely available food supplement with a low risk safety profile)
Number of subjects: 0
Study: 23663287

Group type: EXPERIMENTAL
Intervention: General SAPS3
Number of subjects: 4617

Group type: EXPERIMENTAL
Intervention: Australasia SAPS3
Number of subjects: 4617

Group type: EXPERIMENTAL
Intervention: Customized SAPS3 for Korean ICU patients
Number of subjects: 4617

Group type: COMPARATOR
Intervention: ICU mortality
Number of subjects: 4617

Group type: COMPARATOR
Intervention: Hospital mortality
Number of subjects: 4617
Study: 21311504

Group type: EXPERIMENTAL
Intervention: 60,000 IU monthly oral vitamin D(3) for 16 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 57
Study: 18757052

Group type: EXPERIMENTAL
Intervention: Familiarity based on activated representations in long-term memory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recollection accessing feature bindings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Familiarity based on matching letters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recollection using binding information
Number of subjects: 0
Study: 17227200

Group type: EXPERIMENTAL
Intervention: Multicondition care management system
Number of subjects: 120
Study: 15652899

Group type: EXPERIMENTAL
Intervention: Isolated isoflavones (114 mg daily for 3 months)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 12476384

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with ropivacaine and sufentanil
Number of subjects: 20